Recombinant Borna disease virus Envelope glycoprotein p57 (G), partial

What is the molecular structure of Borna disease virus glycoprotein p57?

The BDV glycoprotein p57 is encoded by the full-length ORF-IV gene and consists of 503 amino acids with an approximate molecular mass of 56.5 kDa before post-translational modifications. The protein contains several key structural features including two hydrophobic amino acid sequences at the N and C termini serving as signal sequence (amino acids 1-20) and transmembrane domain (amino acids 468-492), respectively . Additionally, two other hydrophobic sequences are present between positions 274 and 315, along with three potential furin recognition motifs at arginine residues 249, 364, and 386 . Through extensive glycosylation, the protein's molecular mass increases to approximately 94 kDa (gp94), which is then processed by the cellular protease furin into two distinct fragments that serve different functions in the viral life cycle .

What are the primary functions of BDV glycoprotein p57 in viral infection?

BDV glycoprotein p57 plays multiple critical roles in the viral infectious process. The glycoprotein serves as the primary mediator for receptor recognition and cell entry, with the GP1 (N-terminal fragment) being sufficient for virus receptor binding . Following receptor attachment, GP2 (C-terminal fragment) facilitates the pH-dependent fusion between viral and endosomal membranes, which is essential for delivering the viral ribonucleoprotein (RNP) core into the cytoplasm . Both the full-length glycoprotein (gp94) and its C-terminal cleavage product (GP-43/GP2) have been associated with infectious particles and are proposed to function during early infection events . Research using recombinant vesicular stomatitis virus (VSV) pseudotyped with BDV G has confirmed that this glycoprotein is strictly required for generating infectious virus particles and is a determinant of viral tropism .

What recombinant systems are available for studying BDV glycoprotein p57?

Several sophisticated recombinant systems have been developed to study BDV glycoprotein p57 structure and function. One prominent approach involves pseudotyping vesicular stomatitis virus (VSV) with BDV G protein. Researchers have generated recombinant VSV with its endogenous G protein gene replaced by the green fluorescent protein gene (VSVΔG*), which can then be complemented with BDV p56 to create infectious VSVΔG*/BDVG pseudotypes . This system has been instrumental in investigating the domains of BDV p56 involved in virus entry through receptor-mediated endocytosis and pH-dependent fusion . Additionally, researchers have utilized recombinant vaccinia viruses expressing BDV G (rVV/BDVG) to study glycoprotein processing and function . These systems provide controlled environments to investigate specific aspects of glycoprotein biology without the complexity of full BDV infection, enabling detailed structure-function analyses of distinct domains and mutations .

How can siRNA screening be utilized to identify host factors involved in BDV glycoprotein-mediated entry?

RNA interference (RNAi) screening provides a powerful approach for identifying host cellular factors involved in BDV glycoprotein-mediated viral entry. A comprehensive methodology employs a three-step process utilizing rVSVΔG*/BDVG pseudotyped viruses as a screening tool . The first step involves reverse transfection of cells (e.g., Ol oligodendrocyte cells, which show high susceptibility to BDV infection) with siRNA libraries targeting the human druggable genome . After 36 hours of transfection, cells are infected with rVSVΔG*/BDVG, and initial hits are selected based on increased cell resistance to cytopathic effects (CPE) . The second step compares the susceptibility of cells transfected with potential hit siRNAs to both rVSVΔG*/BDVG and rVSVΔG*/VSVG (control), which allows for identification of factors specifically involved in BDV G-mediated entry rather than general VSV replication . The final validation step confirms the identified hits using authentic BDV infection . Cell viability can be quantitatively measured using ATP-based luminometry assays, providing a reliable readout with excellent dynamic range .

What experimental approaches can determine the domains of BDV glycoprotein p57 essential for viral entry?

Determining functional domains within BDV glycoprotein p57 requires sophisticated domain mapping approaches. A systematic methodology employs the creation of chimeric constructs where domains of BDV p56 are exchanged with corresponding regions from other viral glycoproteins, such as VSV G . These chimeric constructs can then be expressed in appropriate cell systems and assessed for their ability to complement VSVΔG* pseudotypes . Functional pseudotypes indicate that the specific BDV G domains retain entry functionality. Additionally, site-directed mutagenesis targeting specific regions, such as potential receptor-binding sites, furin cleavage sites, or hydrophobic fusion domains, provides insights into the functional significance of these elements . The infectivity of the resulting pseudotyped particles can be quantitatively measured through viral titer determination, fluorescence microscopy of GFP-expressing pseudotypes, or cell viability assays . Complementary approaches include analyzing protein expression, processing, and subcellular localization through techniques like immunofluorescence, Western blotting, and deglycosylation assays .

What are the optimal conditions for expressing functional recombinant BDV glycoprotein p57?

Expressing functional recombinant BDV glycoprotein p57 presents several technical challenges requiring optimization of expression systems and conditions. For successful expression, mammalian cell systems are preferred over bacterial systems due to the requirement for proper post-translational modifications, particularly N-linked glycosylation, which is crucial for protein functionality . Commonly used cell lines include BHK-21, Ol cells, and CHO cells . Transient expression can be achieved using plasmid vectors containing the full-length ORF-IV under control of strong promoters such as CMV . For the construction of expression vectors, the complete ORF-IV gene can be cloned into appropriate mammalian expression vectors such as pcDNA3, using restriction enzymes like BamHI and EcoRI . Verification of correct sequence and orientation is essential before transfection, which can be performed using standard methods like calcium phosphate precipitation or lipid-based transfection reagents . Expression should be validated through Western blotting using antibodies specific to BDV G protein, keeping in mind that the high glycan content may affect antibody recognition, particularly for the GP1 fragment .

How can researchers overcome challenges in detecting and purifying BDV glycoprotein fragments?

Detection and purification of BDV glycoprotein fragments present significant challenges due to extensive glycosylation and proteolytic processing. For detection via Western blotting, samples should be properly denatured by boiling in the presence of reducing agents before separation on 10% acrylamide gels . Transfer to Immobilon membranes followed by blocking with appropriate reagents (e.g., Roche blocking reagent) and probing with specific primary antibodies (typically at 1:1,000 dilution) can effectively detect the various forms of the glycoprotein . When analyzing GP1, researchers should consider that its high N-glycan content may shield antigenic epitopes, making detection challenging with conventional antibodies . To overcome this, deglycosylation treatments using enzymes like PNGase F can reveal hidden epitopes . For purification of recombinant glycoprotein fragments, affinity tags (such as His-tag or FLAG-tag) can be incorporated at either terminus, though care must be taken to ensure these modifications don't interfere with protein folding or function. Purification under native conditions using appropriate buffers that maintain protein conformation is recommended for functional studies, while denaturing conditions may provide higher yields for structural analyses .

What controls are essential when studying BDV glycoprotein-mediated cell entry?

Implementing appropriate controls is critical when studying BDV glycoprotein-mediated cell entry to ensure experimental validity and data interpretation. When using pseudotyped viruses such as rVSVΔG*/BDVG, parallel experiments should include pseudotypes expressing the native VSV G protein (rVSVΔG*/VSVG) as a positive control to verify the functionality of the pseudotyping system . Additionally, "bald" particles lacking any glycoprotein serve as important negative controls to establish baseline levels of non-specific entry . When conducting siRNA-based screens to identify host factors involved in viral entry, non-targeting siRNAs must be included to control for non-specific effects of the transfection process . Cell viability assays should incorporate mock-infected cells as controls to establish a dynamic range for infection-induced cytopathic effects . For validation of potential hits from screens, secondary assays using authentic BDV rather than pseudotyped systems provide essential confirmation of biological relevance . When analyzing glycoprotein processing, wild-type and mutant constructs affecting furin cleavage sites should be compared under identical conditions . All experiments should include technical replicates (minimum triplicate) and biological replicates to ensure reproducibility and statistical significance of observed effects .

How should researchers interpret differences in cell tropism mediated by BDV glycoprotein p57?

Interpreting differences in cell tropism mediated by BDV glycoprotein p57 requires careful experimental design and comprehensive data analysis. When evaluating tropism using pseudotyped systems like rVSVΔG*/BDVG, researchers should examine multiple cell lines derived from different tissues and species to establish broad tropism patterns . Quantitative assessment of infection efficiency can be performed using flow cytometry for GFP-expressing pseudotypes, luminescence-based viability assays, or viral titer determination . Differences in tropism should be analyzed relative to positive controls (such as VSV G pseudotypes) to normalize for variation in general susceptibility to viral infection . Tropism differences may reflect variation in receptor expression, endocytosis pathways, or fusion capacity across cell types. To distinguish between these possibilities, time-course experiments examining binding, internalization, and fusion steps separately can provide mechanistic insights . Additionally, comparative analyses of glycoprotein processing in permissive versus non-permissive cells might reveal cell-specific differences in post-translational modifications affecting function . Statistical analysis should employ appropriate methods (e.g., ANOVA with post-hoc tests) to determine significance of observed tropism differences, and findings should be interpreted within the context of known BDV biology and pathogenesis .

What approaches can distinguish between effects on BDV G protein processing versus function?

Distinguishing between effects on BDV glycoprotein processing versus function requires parallel analyses of protein maturation and functional activity. A comprehensive approach includes biochemical assessment of glycoprotein processing alongside functional assays of viral entry. Western blotting with antibodies specific to different regions of the glycoprotein can detect the various processing intermediates (gp94, GP1/GP-51, GP2/GP-43), allowing quantification of processing efficiency under different conditions . Pulse-chase experiments with metabolic labeling can track the kinetics of glycoprotein synthesis, glycosylation, and proteolytic processing . To specifically evaluate furin-mediated cleavage, researchers can utilize furin inhibitors (e.g., decanoyl-RVKR-chloromethylketone) or cell lines deficient in furin activity, comparing glycoprotein processing patterns with those in wild-type conditions . In parallel, functional assays using pseudotyped viruses (rVSVΔG*/BDVG) can assess the impact of altered processing on viral entry efficiency . By correlating changes in processing patterns with alterations in viral entry activity, researchers can determine whether specific interventions primarily affect protein maturation or the intrinsic function of properly processed glycoprotein . Mutations targeting specific domains, particularly the furin cleavage sites or receptor-binding regions, can provide further insights into the relationship between processing and function .

How can researchers validate host factors identified in screens for BDV glycoprotein-mediated entry?

Validating host factors identified in screens for BDV glycoprotein-mediated entry requires a multifaceted approach to confirm biological relevance and specificity. Following initial identification through siRNA-based screening using rVSVΔG*/BDVG pseudotypes, researchers should first confirm the knockdown efficiency of the siRNAs targeting the candidates using quantitative RT-PCR and Western blotting to verify reduction in mRNA and protein levels, respectively . Next, the specificity of the effect should be assessed by comparing the impact on rVSVΔG*/BDVG versus rVSVΔG*/VSVG infection, ensuring that observed effects are specific to BDV G-mediated entry rather than general VSV replication . Critical validation requires demonstrating the relevance of identified factors in authentic BDV infection, not just pseudotyped systems . This can be accomplished by siRNA-mediated knockdown of candidate genes followed by infection with bona fide BDV and assessment of infection efficiency through immunofluorescence for viral proteins, RT-PCR for viral RNA, or other appropriate assays . Complementation experiments, where expression of siRNA-resistant versions of the candidate genes restores susceptibility to infection, provide strong evidence for specificity and rule out off-target effects . Finally, mechanistic studies to determine how the identified host factors interact with the viral glycoprotein or influence specific steps in the entry process (attachment, endocytosis, fusion) further validate their biological significance in BDV pathogenesis .

What are promising approaches for developing inhibitors targeting BDV glycoprotein p57?

Developing inhibitors targeting BDV glycoprotein p57 represents an important research direction with both basic science and potential therapeutic implications. A structure-guided approach would begin with detailed structural characterization of the glycoprotein, particularly the receptor-binding domain within GP1 and the fusion machinery in GP2 . Computational modeling and docking studies can identify potential binding pockets suitable for small molecule inhibitors . High-throughput screening of compound libraries using the rVSVΔG*/BDVG pseudotype system provides an efficient initial approach to identify candidates that specifically block BDV G-mediated entry . Promising compounds should be evaluated for their mechanism of action, distinguishing between those that interfere with receptor binding versus fusion processes . Peptide-based inhibitors derived from the GP2 fusion domain, designed to disrupt conformational changes required for fusion, represent another promising approach based on successful strategies against other enveloped viruses . Additionally, biologics targeting the glycoprotein, such as neutralizing antibodies or soluble receptor mimics, could be developed and evaluated using pseudotype systems before testing against authentic BDV . Finally, molecules interfering with host proteases required for glycoprotein processing, particularly furin inhibitors, might offer an indirect strategy to prevent formation of functional viral glycoproteins .

How might structural studies of BDV glycoprotein advance understanding of virus-host interactions?

Advanced structural studies of BDV glycoprotein would significantly enhance our understanding of virus-host interactions at the molecular level. X-ray crystallography of purified, properly folded glycoprotein fragments (particularly the receptor-binding domain of GP1) would reveal the precise three-dimensional arrangement of amino acids involved in host receptor recognition . Cryo-electron microscopy of intact virions or virus-like particles could provide insights into the arrangement and density of glycoprotein spikes on the viral surface . Hydrogen-deuterium exchange mass spectrometry could identify regions undergoing conformational changes during the fusion process triggered by low pH, illuminating the fusion mechanism . Structural studies of GP1 in complex with its cellular receptor (once identified through complementary approaches) would reveal the molecular basis of cell tropism and species specificity . Comparative structural analyses of glycoproteins from different BDV strains might explain variations in pathogenicity or host range . Modern approaches like AlphaFold could complement experimental structural biology by predicting structures of glycoprotein domains for which crystallization proves challenging. These structural insights would inform rational design of entry inhibitors, guide development of improved vaccines or diagnostic tools, and advance our fundamental understanding of viral membrane fusion mechanisms across the Mononegavirales order .

What is the potential for using BDV glycoprotein pseudotyped systems in gene therapy applications?

The potential application of BDV glycoprotein pseudotyped systems in gene therapy represents an innovative frontier in BDV research. BDV exhibits neurotropism and persistent infection capabilities that could be harnessed for developing gene delivery vectors targeting the central nervous system . Pseudotyped systems like rVSVΔG*/BDVG provide a foundation for such applications, where the BDV glycoprotein confers specific tropism while the vector backbone carries therapeutic genetic material . To advance this application, comprehensive characterization of BDV G-mediated tropism across multiple neuronal and glial cell types is essential, identifying the most efficiently targeted neural populations . Engineering modified glycoproteins with enhanced specificity for particular neural cell types could improve targeting precision, potentially through directed evolution approaches or rational design based on structural insights . Safety considerations would necessitate modifications to prevent potential inflammatory responses in the brain, particularly given BDV's association with neurological disorders . Integration with other viral vector systems beyond VSV, such as lentiviral or adeno-associated viral vectors, might optimize stability and expression duration of delivered genes . Preclinical testing in relevant animal models would be required to assess efficacy, safety, and the persistence of gene expression mediated by such vectors before consideration for clinical applications .